论文部分内容阅读
目的:通过体外研究探讨光敏剂photofrinⅡ预激活后对人白血病K562细胞株的杀伤作用及其与化疗药物配伍能否产生协同或拮抗效应。方法:以K562细胞株为研究对象,采用MTT法检测photofrinⅡ预激活后对K562细胞株的抑制作用,同时检测photofrinⅡ预激活后分别与顺铂(DDP)、5-氟脲嘧啶(5-FU)、阿霉素(ADM)联合应用对K562细胞的杀伤作用,Burgi法分析联合用药效果。结果:photofrinⅡ预激活后能明显抑制K562细胞株的增殖,并且这种作用呈剂量依赖性,但其抑瘤作用较后激活组降低。photofrinⅡ预激活后分别与DDP、5-FU、ADM联合,增加了化疗药物的抑瘤作用。结论:photofrinⅡ预激活后能够抑制K562细胞株的增殖,与DDP、5-FU、ADM联合使用具有相加作用。
OBJECTIVE: To investigate the killing effect of photofrin Ⅱ pretreatment on human leukemia K562 cell line and its synergistic or antagonistic effect with chemotherapeutics in vitro. Methods: The K562 cell line was used as a research object. The inhibitory effect of photofrin Ⅱ pretreatment on K562 cell line was detected by MTT assay. Meanwhile, the inhibitory effects of photofrin Ⅱ pretreatment and cisplatin (DDP), 5-fluorouracil (5-FU) , Doxorubicin (ADM) in combination with K562 cells, Burgi method to analyze the effect of combination therapy. RESULTS: Pretreatment with photofrin Ⅱ significantly inhibited the proliferation of K562 cells in a dose-dependent manner. However, the anti-tumor effect of photofrinⅡ was significantly lower than that of the K562 cells. Photofrin Ⅱ pre-activation, respectively, with DDP, 5-FU, ADM combined, increased the anti-tumor effect of chemotherapy drugs. CONCLUSION: Pre-activation of photofrinⅡ can inhibit the proliferation of K562 cell line, and can be used in combination with DDP, 5-FU and ADM.